ReviewCurrent atherosclerosis reports2004
Hepatic lipase: friend or foe and under what circumstances?
Review in Current atherosclerosis reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 25 citations in OpenAlex.
- The Proline 7 Substitution in the Preproneuropeptide Y Is Associated with Higher Hepatic Lipase Activity In Vivo.International journal of endocrinology · 2017Article
- Effects of exercise training on intrahepatic lipid content in humans.Diabetologia · 2016Review
- LIGHT/TNFSR14 can regulate hepatic lipase expression by hepatocytes independent of T cells and Kupffer cells.PloS one · 2013Article
- Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.Circulation · 2012Review
- The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype.Biochimica et biophysica acta · 2012Review
- Positive association of the hepatic lipase gene polymorphism c.514C > T with estrogen replacement therapy response.Lipids in health and disease · 2011Article
- The eSS rat, a nonobese model of disordered glucose and lipid metabolism and fatty liver.Diabetology & metabolic syndrome · 2010Article
- The metabolism and anti-atherogenic properties of HDL.Journal of lipid research · 2009Review
- High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease.Vascular health and risk management · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic lipase (HL) plays a role in the metabolism of chylomicron and very low-density lipoprotein remnants, low-density lipoproteins (LDL), and high-density lipoproteins (HDL), which are all implicated in atherosclerosis. Considering the effects of HL on these lipoproteins, it appears that HL has pro- as well as antiatherogenic potential. In line with clinical observations, most effects of HL on lipoprotein metabolism during hypertriglyceridemia may be interpreted as promoting atherosclerosis (formation of small, dense LDL, lowering of HDL levels), whereas most effects during hypercholesterolemia seem to be potentially antiatherogenic (stimulation of reverse cholesterol transport, clearing of intermediate-density lipoprotein). The potential modulation of pro- or antiatherogenics effect of HL by other factors, such as LDL receptor, cholesterol ester transfer protein, lipoprotein lipase, and ATP-binding cassette A-1 activity, is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.